These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1432610)

  • 61. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences.
    Altamura C; Mauri M; Cavallaro R; Colacurcio F; Gorni A; Bareggi S
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(5):689-94. PubMed ID: 3222450
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
    Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
    Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The measurement of haloperidol and reduced haloperidol in neonatal hair as an index of placental transfer of maternal haloperidol.
    Uematsu T; Yamada K; Matsuno H; Nakashima M
    Ther Drug Monit; 1991 Mar; 13(2):183-7. PubMed ID: 2053128
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol.
    Midha KK; Chakraborty BS; Ganes DA; Hawes EM; Hubbard JW; Keegan DL; Korchinski ED; McKay G
    J Clin Psychopharmacol; 1989 Apr; 9(2):98-104. PubMed ID: 2723140
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
    Jann MW; Chang WH; Lam YW; Hwu HG; Lin HN; Chen H; Chen TY; Lin SK; Chien CP; Davis CM
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):193-202. PubMed ID: 1579637
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients.
    Ishizaki T; Chiba K; Saito M; Kobayashi K; Iizuka R
    J Clin Psychopharmacol; 1984 Oct; 4(5):254-61. PubMed ID: 6149238
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intra- and interethnic variability in reduced haloperidol to haloperidol ratios.
    Lam YW; Jann MW; Chang WH; Yu HS; Lin SK; Chen H; Davis CM
    J Clin Pharmacol; 1995 Feb; 35(2):128-36. PubMed ID: 7751421
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 70. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol.
    Pelton GH; Devanand DP; Bell K; Marder K; Marston K; Liu X; Cooper TB
    Am J Geriatr Psychiatry; 2003; 11(2):186-93. PubMed ID: 12611748
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Blood levels of haloperidol in schizophrenic patients.
    Shvartsburd A; Dekirmenjian H; Smith RC
    J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
    Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
    Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Using ofloxacin as a time marker in hair analysis for monitoring the dosage history of haloperidol.
    Nakano M; Uematsu T; Sato H; Kosuge K; Nishimoto M; Nakashima M
    Eur J Clin Pharmacol; 1994; 47(2):195-202. PubMed ID: 7859809
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The plasma levels of haloperidol and reduced haloperidol in Japanese psychiatric patients].
    Someya T; Shibasaki M; Takahashi S
    Yakubutsu Seishin Kodo; 1989 Jun; 9(2):207-15. PubMed ID: 2816093
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms.
    Eyles DW; Stedman TJ; Pond SM
    Psychopharmacology (Berl); 1994 Oct; 116(2):161-6. PubMed ID: 7862945
    [TBL] [Abstract][Full Text] [Related]  

  • 79. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.
    Otani K; Ishida M; Yasui N; Kondo T; Mihara K; Suzuki A; Kaneko S; Inoue Y; Shibata M; Ikeda K
    Ther Drug Monit; 1997 Apr; 19(2):165-8. PubMed ID: 9108644
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.
    Jann MW; Saklad SR; Ereshefsky L; Richards AL; Harrington CA; Davis CM
    Psychopharmacology (Berl); 1986; 90(4):468-70. PubMed ID: 3101102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.